ਫੇਫੜਿਆਂ ਦਾ ਕੈਂਸਰ (non-small cell)
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
ਕਿੱਥੇ ਜਾਣਾ ਹੈ
ਭਾਰਤ ਦੀਆਂ 6 ਹਸਪਤਾਲ ਇਸ ਟ੍ਰਾਇਲ ਲਈ ਮਰੀਜ਼ ਲੈ ਰਹੀਆਂ ਹਨ।
ਰਜਿਸਟਰੀ ਸਮਰੀ (ਤਕਨੀਕੀ)
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) …
ਸਪਾਂਸਰ: Pfizer
ClinicalTrials.gov 'ਤੇ NCT06758401
ਰਜਿਸਟਰੀ ਵਿੱਚ ਆਖਰੀ ਵਾਰ 25 Sep 2026 ਨੂੰ ਅੱਪਡੇਟ ਕੀਤਾ ਗਿਆ · ਅਸੀਂ 20 Oct 2026 ਨੂੰ ਪੜ੍ਹਿਆ